Ali Ipakchi, MD
Nephrology · Greenbelt, MDNPI 1487618773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$809
- Mallinckrodt Hospital Products Inc.$556
- Amgen$526
- Otsuka America Pharmaceutical, Inc.$386
- Boehringer Ingelheim$320
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,80395%
- Education$3515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 66 | $1,407 |
| Bayer | 42 | $809 |
| Mallinckrodt Hospital Products Inc. | 19 | $556 |
| Amgen(2 entities) | 22 | $526 |
| Otsuka America Pharmaceutical, Inc. | 20 | $386 |
| Boehringer Ingelheim | 14 | $320 |
| Mallinckrodt Enterprises LLC | 8 | $299 |
| Vifor Pharma, Inc. | 14 | $273 |
| Fresenius USA Marketing, Inc. | 12 | $256 |
| Calliditas Therapeutics US Inc. | 11 | $254 |
| Lilly USA, LLC | 8 | $242 |
| Travere Therapeutics, Inc. | 19 | $237 |
| Novartis | 9 | $236 |
| Aurinia Pharma U.S., Inc. | 8 | $179 |
| Akebia Therapeutics Inc | 9 | $171 |
| Alnylam Pharmaceuticals Inc. | 8 | $153 |
| ANI Pharmaceuticals, Inc. | 5 | $134 |
| OPKO Pharmaceuticals, LLC | 6 | $129 |
| GSK | 6 | $120 |
| Ardelyx, Inc. | 4 | $96 |
| Acclarent, Inc | 1 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Biomerieux Inc | 4 | $61 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| Shield Therapeutics Inc | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
How this compares
$7,155 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $88,211 |
| VelphoroSucroferric Oxyhydroxide | 22 | $74,514 |
| FarxigaDapagliflozin Propanediol | 55 | $67,832 |
| KerendiaFinerenone | 33 | $51,053 |
| LokelmaSodium Zirconium Cyclosilicate | 30 | $40,109 |
| ClinisolParenteral Amino Acid 15% No.5 | 52 | $7,229 |
| Sevelamer Carbonate | 19 | $3,341 |
| Potassium Citrate ErPotassium Citrate | 20 | $3,208 |
| Hydralazine Hcl | 92 | $3,071 |
| Calcitriol | 121 | $2,239 |
| Amlodipine Besylate | 83 | $1,379 |
| Nifedipine ErNifedipine | 21 | $1,198 |
| Doxazosin Mesylate | 49 | $840 |
| Metoprolol Succinate | 40 | $831 |
| Losartan Potassium | 64 | $819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,407 | $107,94185 claims |
| Boehringer IngelheimJardiance | $320 | $88,21171 claims |
| Fresenius USA Marketing, Inc.Velphoro | $256 | $74,51422 claims |
| BayerKerendia | $809 | $51,05333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 nephrology providers in Maryland.
Other nephrology in Greenbelt
- Atul SuriGreenbelt$30K
- Quan WangGreenbelt$16K
- Jonathan RudickGreenbelt$7K
- Vishwam PandyaGreenbelt$6K
- Nirmala YadlaGreenbelt$3K
- Promod DuggalGreenbelt$3K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.